Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo
Launched by UNIVERSITY OF BRITISH COLUMBIA · Jan 10, 2013
Trial Information
Current as of June 12, 2025
Unknown status
Keywords
ClinConnect Summary
Vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin and mucous membranes. Mucocutaneous lesions develop secondary to selective destruction of melanocytes. It has a major psychosocial impact on affected patients. The etiology of vitiligo is largely unknown but more likely to be multifactorial. There are several theories on the pathogenesis of vitiligo including mainly the autoimmune, neurohormonal, and autocytotoxic theories. The autoimmune hypothesis has the strongest evidence with alteration mainly in the cellular immune respons...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years.
- • Localized or generalized vitiligo that involves a non mucosal or acral site.
- • Patients should have a patch of at least 5 cm in the smallest diameter that shows no more than 10% repigmentation as assessed visually
- Exclusion Criteria:
- • Patients who received treatment for vitiligo within the past 4 weeks.
- • Hypersensitivity to TA or vehicle.
- • Pregnancy or breast-feeding.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Harvey Lui, MD, FRCPC
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials